Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Catalent Inc Stock Research

CTLT

45.78USD+0.15(+0.33%)Market Closed
Watchlist

Market Summary

USD45.78+0.15
Market Closed
0.33%

CTLT Alerts

  • 2 major insider buys recently.

CTLT Stock Price

CTLT RSI Chart

CTLT Valuation

Market Cap

8.2B

Price/Earnings (Trailing)

515.03

Price/Sales (Trailing)

1.84

EV/EBITDA

47.29

Price/Free Cashflow

-14.64

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

0.44%

Return on Equity

0.47%

Return on Assets

0.2%

Free Cashflow Yield

-6.83%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.5B

Revenue Y/Y

-18.54%

Revenue Q/Q

-9.75%

CTLT Earnings

Earnings (TTM)

16.0M

Earnings Y/Y

-260.99%

Earnings Q/Q

-383.75%

Price Action

52 Week Range

31.4581.72
(Low)(High)

Last 7 days

-4.0%

Last 30 days

1.7%

Last 90 days

13.1%

Trailing 12 Months

-38.9%

CTLT Financial Health

Current Ratio

1.84

Debt/Equity

0.91

Debt/Cashflow

0.03

CTLT Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CTLT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-10
Barg Steven
acquired
-
-
718
-
2023-08-31
Ryan Michelle R
bought
49,980
49.98
1,000
-
2023-08-30
GREISCH JOHN J
bought
1,055,040
50.24
21,000
executive chair
2023-08-28
Ryan Michelle R
acquired
-
-
979
-
2023-08-28
DAMELIO FRANK A
acquired
-
-
979
-
2023-08-28
Okey Stephanie
acquired
-
-
979
-
2023-08-24
Gennadios Aristippos
sold
-17,618
44.49
-396
group pres. pharma & consumer
2023-08-24
Carletti Lorenzo
sold
-9,657
44.71
-216
svp global ops ph & cons hlth
2023-08-24
Pravda Ricardo
sold
-16,854
44.47
-379
chief transformation officer
2023-08-24
Grippo Michael J
sold
-17,355
44.5
-390
svp, strategy & corp. dev.

1–10 of 50

Which funds bought or sold CTLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
sold off
-100
-720,116
-
-%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
-2,079
4,032
-%
2023-09-20
BARCLAYS PLC
added
606
115,299,000
146,802,000
0.09%
2023-09-12
Farther Finance Advisors, LLC
reduced
-35.00
-6,005
4,509
-%
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
added
133
6,612,240
18,768,600
0.48%
2023-08-29
EFG Asset Management (Americas) Corp.
sold off
-100
-2,316,800
-
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-117,919
228,767
0.01%
2023-08-24
ProVise Management Group, LLC
new
-
619,354
619,354
0.06%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-250,499
485,979
-%
2023-08-23
Stonebridge Capital Advisors LLC
unchanged
-
-25,367
49,214
-%

1–10 of 44

Latest Funds Activity

Are funds buying CTLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CTLT
No. of Funds

Schedule 13G FIlings of Catalent

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
9.2%
16,578,946
SC 13G/A
Feb 13, 2023
capital world investors
7.7%
13,914,820
SC 13G/A
Feb 09, 2023
janus henderson group plc
4.6%
8,216,242
SC 13G/A
Feb 09, 2023
vanguard group inc
10.88%
19,588,103
SC 13G/A
Feb 07, 2023
blackrock inc.
7.7%
13,788,094
SC 13G/A
Jan 27, 2023
veritas asset management llp
6.21%
11,169,815
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
10.8%
18,616,482
SC 13G/A
Feb 11, 2022
capital world investors
6.2%
10,577,293
SC 13G
Feb 09, 2022
vanguard group inc
10.79%
18,479,271
SC 13G/A
Feb 03, 2022
blackrock inc.
8.8%
14,998,086
SC 13G/A

Recent SEC filings of Catalent

View All Filings
Date Filed Form Type Document
Sep 15, 2023
8-K
Current Report
Sep 12, 2023
3
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 11, 2023
8-K
Current Report
Sep 05, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
NT 10-K
NT 10-K
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading

CTLT Fair Value

Loading...

Peers (Alternatives to Catalent)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
494.6B
29.5B
-0.66% 79.36%
76.12
16.76
1.53% 14.16%
408.2B
97.8B
-4.35% -2.72%
31.27
4.18
2.29% -28.92%
272.8B
58.3B
-4.37% 23.96%
17.88
4.63
2.00% -81.24%
181.2B
77.9B
-10.94% -25.44%
8.44
2.33
-23.04% -26.74%
150.1B
45.2B
-5.70% -15.91%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.99% 679.20%
-74.1
4.1K
-86.94% 71.24%
4.3B
4.6B
-16.08% -16.44%
-62.93
0.92
6.60% 42.04%
SMALL-CAP
1.6B
634.0M
-6.94% -10.23%
36.56
2.5
0.62% -24.59%
1.6B
627.1M
-7.75% -11.11%
-1.08
2.51
-0.20% -204.67%
858.4M
244.3M
-1.05% 13.25%
4.35
3.51
-39.50% -4.99%
788.9M
109.5M
24.85% -25.44%
-5.5
7.2
-2.66% -32.13%
489.9M
453.3M
136.46% -66.34%
-0.4
1.08
-16.04% 55.90%
471.3M
31.2M
-3.91% -52.16%
-4.48
15.12
407.54% -26.47%
255.1M
54.6M
-17.22% -39.02%
-2.81
4.67
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Catalent News

Best Stocks
Significant Block Trade of CTLT Shares Shakes Securities Market.
Best Stocks,
3 hours ago
InvestorsObserver
Yahoo Entertainment
Marketscreener.com
InvestorsObserver

Returns for CTLT

Cumulative Returns on CTLT

8.2%


7-Year Cumulative Returns

0.2%


5-Year Cumulative Returns

-17.7%


3-Year Cumulative Returns

Risks for CTLT

What is the probability of a big loss on CTLT?

75.4%


Probability that Catalent stock will be more than 20% underwater in next one year

65.8%


Probability that Catalent stock will be more than 30% underwater in next one year.

20.8%


Probability that Catalent stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CTLT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalent was unfortunately bought at previous high price.

Drawdowns

Financials for Catalent

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q12018Q42018Q32018Q22018Q12017Q4
Revenue-5.0%4,4884,7244,7924,8024,7034,4834,1773,9985,9045,6125,4225,2412,8622,6712,5402,4782,4882,4712,4632,3952,300
Gross Profit-16.0%1,2801,5231,5411,6141,5911,5341,4271,3521,2481,1201,055983905865834782775761753734710
  S&GA Expenses-2.0%838855857844802768705687660623599577563557539494481473465447431
EBITDA-61.4%284735772860843967940894856550481388267289-------
EBITDA Margin-59.3%0.06*0.16*0.16*0.18*0.18*0.22*0.23*0.22*0.23*0.16*0.15*0.13*0.09*0.11*-------
Interest Expenses-12.5%-162-144-129-123-123-117-111-110-99.40-106-115-126-136-128-119-110-113-115-111-104-96.70
Earnings Before Taxes-97.2%13.00471472579615756750715672384334260161174167170160137152132134
EBT Margin-95.6%0.00*0.10*0.10*0.13*0.13*0.17*0.18*0.18*0.18*0.11*0.10*0.08*0.06*0.06*-------
Net Income-95.8%16.0038440149951360459558555634530322113814815214913665.0084.0063.0070.00
Net Income Margin-94.1%0.00*0.08*0.09*0.11*0.11*0.13*0.14*0.15*0.15*0.10*0.09*0.07*0.05*0.05*-------
Free Cashflow-51.8%-563-371-471-221-110-182-244-253-188-13423.00-25.50-36.7020.00-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-3.0%10,50810,83011,14810,20610,50810,32210,20310,1839,1128,7698,1987,9847,7777,0806,1956,1206,1844,4934,4424,5004,531
  Current Assets6.5%2,9172,7382,9192,6992,9173,0252,9743,9312,9182,7752,5192,3562,2931,7461,3011,2671,3961,1441,0721,0831,240
    Cash Equivalents-100.0%-2524422814497868491,9698969888331,007953608189243345228208266410
  Inventory-100.0%-744818732702676688622563528461384324297250251257247235236209
  Net PPE-100.0%-3,6713,5793,1673,1272,8202,7272,5812,5242,3592,1302,0361,9011,7701,6181,5611,5371,3021,2861,2881,271
  Goodwill-100.0%-3,0233,2152,9293,0063,0123,0262,5312,5192,5152,4622,4902,4712,4492,2082,1962,2211,4091,4211,4351,397
Liabilities-6.4%5,7336,1276,2565,5265,7335,6905,7225,8034,8384,6974,3844,3064,2714,2853,8733,8643,896---3,444
  Current Liabilities-26.2%1,0981,4871,5529691,0981,0461,0451,0961,1961,1391,024920893917658616671525514528577
  Long Term Debt-100.0%-4,2614,2214,0984,1714,1574,1914,2253,1663,1502,9842,9852,9452,9272,8252,8592,8832,1162,1302,2062,649
Shareholder's Equity1.5%4,7754,7034,8924,6804,7754,6324,4814,0213,9153,7133,4563,0722,8992,1881,7161,6491,6821,6211,5631,5291,086
  Retained Earnings39.2%51837261951851835020911425.00-150-377-460-535-681-694-731-723-790-822-871-872
  Additional Paid-In Capital-100.0%-4,6974,6864,6744,6494,6304,6154,2344,2054,1864,1613,9013,8183,2612,7592,7552,7572,7392,7352,7342,283
Accumulated Depreciation-100.0%-1,5401,4651,3581,3471,3081,2151,2151,179------------
Shares Outstanding-100.0%-180180180179179171171171170170165163155146146146145145145133
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Cashflow From Operations-61.4%127329184439504441446433471518565440356309232248263283332375371
  Share Based Compensation-7.8%47.0051.0052.0054.0055.0060.0068.0051.0051.00--48.00---33.00--20.0027.0026.00
Cashflow From Investing6.2%-1,228-1,309-1,833-1,884-1,703-1,594-665-649-598-981-893-827-1,917-1,500-1,429-1,510-316-302-1,042-919-912
Cashflow From Financing-3.7%57359523.001,0311,0131,1821,1741424901,0971,0881,0021,9541,1731,1841,201-88.00-87.10387669668
  Buy Backs----------768770-659-0.27-0.27-445446446278278

CTLT Income Statement

2022-06-30
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]   
Revenues$ 4,802,000,000$ 3,998,000,000$ 3,094,000,000
Cost of Goods and Services Sold3,188,000,0002,646,000,0002,111,000,000
Gross Profit1,614,000,0001,352,000,000983,000,000
Selling, General and Administrative Expense844,000,000687,000,000577,000,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal1,000,000182,000,000(1,000,000)
Other Cost and Expense, Operating41,000,00019,000,00011,000,000
Operating Income (Loss)730,000,000828,000,000394,000,000
Interest Income (Expense), Net(123,000,000)(110,000,000)(126,000,000)
Nonoperating Income (Expense)(28,000,000)(3,000,000)(8,000,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest579,000,000715,000,000260,000,000
Income Tax Expense (Benefit)80,000,000130,000,00039,000,000
Net Income (Loss) Attributable to Parent499,000,000585,000,000221,000,000
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic16,000,00056,000,00048,000,000
Net Income (Loss) Available to Common Stockholders, Basic$ 483,000,000$ 529,000,000$ 173,000,000
Earnings Per Share, Basic$ 2.74$ 3.15$ 1.16
Earnings Per Share, Diluted$ 2.73$ 3.11$ 1.14

CTLT Balance Sheet

2022-06-30
Consolidated Balance Sheet - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Statement of Financial Position [Abstract]  
Cash and Cash Equivalents, at Carrying Value$ 449,000,000$ 896,000,000
Accounts Receivable, after Allowance for Credit Loss, Current1,051,000,0001,012,000,000
Inventory, Net702,000,000563,000,000
Prepaid Expense and Other Assets, Current626,000,000376,000,000
Marketable Securities89,000,00071,000,000
Assets, Current2,917,000,0002,918,000,000
Property, Plant and Equipment, Net3,127,000,0002,524,000,000
Goodwill3,006,000,0002,519,000,000
Intangible Assets, Net (Excluding Goodwill)1,060,000,000817,000,000
Deferred Tax Assets, Deferred Income49,000,00066,000,000
Other Assets, Noncurrent349,000,000268,000,000
Assets10,508,000,0009,112,000,000
Debt, Current31,000,00075,000,000
Accounts Payable, Current421,000,000385,000,000
Other Accrued Liabilities, Current646,000,000736,000,000
Liabilities, Current1,098,000,0001,196,000,000
Long-Term Debt and Lease Obligation4,171,000,0003,166,000,000
Liability, Defined Benefit Pension Plan, Noncurrent103,000,000137,000,000
Deferred Tax Liabilities, Tax Deferred Income197,000,000164,000,000
Other Liabilities, Noncurrent164,000,000175,000,000
Liabilities5,733,000,0004,838,000,000
Common Stock, Value, Outstanding2,000,0002,000,000
Preferred Stock, Value, Outstanding 0
Additional Paid in Capital, Common Stock4,649,000,0004,205,000,000
Retained Earnings (Accumulated Deficit)518,000,00025,000,000
Accumulated Other Comprehensive Income (Loss), Net of Tax(394,000,000)(317,000,000)
Equity, Attributable to Parent4,775,000,0003,915,000,000
Liabilities and Equity10,508,000,0009,112,000,000
Redeemable Preferred Stock Outstandings$ 0$ 359,000,000
John R. Chiminski
17300
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.